Ritonavir Accord 100mg film-coated tablets Malta - angličtina - Medicines Authority

ritonavir accord 100mg film-coated tablets

accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - ritonavir - film-coated tablet - ritonavir 100 mg - antivirals for systemic use

HIGHLIGHTS OF PRESCRIBING INFORMATION Spojené státy - angličtina - NLM (National Library of Medicine)

highlights of prescribing information

american health packaging - ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - ritonavir 100 mg - ritonavir tablets are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. - when co-administering ritonavir with other protease inhibitors, see the full prescribing information for that protease inhibitor including contraindication information. - ritonavir is contraindicated in patients with known hypersensitivity (e.g., toxic epidermal necrolysis (ten) or stevens-johnson syndrome) to ritonavir or any of its ingredients. - ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions. - ritonavir is contraindicated with drugs that are potent cyp3a inducers where significantly reduced lopinavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance and cross-resistance. drug class drugs within class that are contraindicated with ritonavir * clinical comments alpha 1 -ad

TECHNIVIE- ombitasvir and paritaprevir and ritonavir kit Spojené státy - angličtina - NLM (National Library of Medicine)

technivie- ombitasvir and paritaprevir and ritonavir kit

abbvie inc. - ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825), ombitasvir heminonahydrate (unii: eqe3i70j3w) (ombitasvir - unii:2302768xj8), paritaprevir dihydrate (unii: hrq5901o78) (paritaprevir - unii:ou2ym37k86) - ritonavir 50 mg - technivie is indicated in combination with ribavirin for the treatment of patients with genotype 4 chronic hepatitis c virus (hcv) infection without cirrhosis or with compensated cirrhosis [see clinical studies (14)] . - the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin. - technivie is contraindicated: in patients with moderate to severe hepatic impairment (child-pugh b and c) due to risk of potential toxicity [see warnings and precautions (5.2), use in specific populations (8.6) and clinical pharmacology (12.3)] . with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events [see drug interactions (7) and clinical pharmacology (12.3)] : alpha1-adrenoreceptor antagonist: alfuzosin hcl anti-anginal: ranolazine antiarrhythmic: dronedarone anti-gout: colchicine in patients with renal and/or hepat

VIEKIRA XR- dasabuvir and ombitasvir and paritaprevir and ritonavir kit Spojené státy - angličtina - NLM (National Library of Medicine)

viekira xr- dasabuvir and ombitasvir and paritaprevir and ritonavir kit

abbvie inc. - ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825), dasabuvir sodium monohydrate (unii: og6d40m62l) (dasabuvir - unii:de54eqw8t1), paritaprevir dihydrate (unii: hrq5901o78) (paritaprevir - unii:ou2ym37k86), ombitasvir heminonahydrate (unii: eqe3i70j3w) (ombitasvir - unii:2302768xj8) - ritonavir 33.33 mg - viekira xr is indicated for the treatment of adult patients with chronic hepatitis c virus (hcv) [see dosage and administration (2.2) and clinical studies (14)] : - genotype 1b infection without cirrhosis or with compensated cirrhosis - genotype 1a infection without cirrhosis or with compensated cirrhosis for use in combination with ribavirin. - if viekira xr is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin. - viekira xr is contraindicated: in patients with moderate to severe hepatic impairment (child-pugh b and c) due to risk of potential toxicity [see warnings and precautions (5.2), use in specific populations (8.6) and clinical pharmacology (12.3)] . with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events [see drug interactions (7) and clinical pharmac

Ritonavir 100 mg film-coated tablet Irsko - angličtina - HPRA (Health Products Regulatory Authority)

ritonavir 100 mg film-coated tablet

accord healthcare ireland ltd. - ritonavir - film-coated tablet - 100 milligram(s) - protease inhibitors; ritonavir

LOPINAVIR AND RITONAVIR- lopinavir and ritonavir tablet, film coated Spojené státy - angličtina - NLM (National Library of Medicine)

lopinavir and ritonavir- lopinavir and ritonavir tablet, film coated

camber pharmaceuticals, inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir and ritonavir tablets are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 14 days and older. limitations of use:  • genotypic or phenotypic testing and/or treatment history should guide the use of lopinavir and ritonavir tablets. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir tablets [see microbiology (12.4)]. • lopinavir and ritonavir tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir. • lopinavir and ritonavir tablets are contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious an

LOPINAVIR AND RITONAVIR tablet, film coated Spojené státy - angličtina - NLM (National Library of Medicine)

lopinavir and ritonavir tablet, film coated

laurus labs limited - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of hiv- 1 infection in adults and pediatric patients 14 days and older. limitations of use: - genotypic or phenotypic testing and/or treatment history should guide the use of  lopinavir and ritonavir. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir [see microbiology (12.4)] . - lopinavir and ritonavir is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir. - lopinavir and ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see drug interactions (7.1) and clinical pharmacology (12.3)] .          

LOPINAVIR AND RITONAVIR tablet, film coated Spojené státy - angličtina - NLM (National Library of Medicine)

lopinavir and ritonavir tablet, film coated

nucare pharmaceuticals,inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of hiv- 1 infection in adults and pediatric patients 14 days and older. limitations of use: - genotypic or phenotypic testing and/or treatment history should guide the use of  lopinavir and ritonavir. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir [ see microbiology (12.4)] . - lopinavir and ritonavir is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir. - lopinavir and ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see